健世科技-B(09877)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

09877 健世科技-B

休市中 07-24 16:08:04

7.590

-0.190

-2.44%

最高7.600	最低7.600	成交量600.00
今开7.600	昨收7.780	日振幅0.00%
总市值31.66亿	流通市值23.55亿	总股本4.17亿
成交额4,556	换手率0.00%	流通股本3.10亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"09877","market":"HK","secType":"STK","nameCN":"健世科技-B","latestPrice":7.59,"timestamp":1784880484049,"preClose":7.78,"halted":0,"volume":600,"delay":0,"changeRate":-0.02442159383033424,"floatShares":310306209,"shares":417167290,"eps":-0.64,"marketStatus":"休市中","change":-0.19,"latestTime":"07-24 16:08:04","open":7.6,"high":7.6,"low":7.6,"amount":4556,"amplitude":0,"askPrice":7.59,"askSize":17000,"bidPrice":6.8,"bidSize":2000,"shortable":3,"etf":0,"ttmEps":-0.709563,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1785115800000},"marketStatusCode":7,"adr":0,"listingDate":1665331200000,"exchange":"SEHK","adjPreClose":7.78,"openAndCloseTimeList":[[1784856600000,1784865600000],[1784869200000,1784880000000]],"volumeRatio":0.026315789508310254,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/09877","defaultTab":"news","newsList":[{"id":"1156630375","title":"健世科技-B公布LuX-Valve Plus在美国关键性注册临床试验完成首批植入","url":"https://stock-news.laohu8.com/highlight/detail?id=1156630375","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1156630375?lang=zh_cn&edition=full","pubTime":"2026-07-16 12:26","pubTimestamp":1784175965,"startTime":"0","endTime":"0","summary":"健世科技-B7月16日自愿公告称，公司自主研发的经导管三尖瓣置换系统LuX-Valve Plus已在美国食品及药品监督管理局批准的关键性注册临床试验中完成首批受试者植入。公司表示，基于LuX-Valve Plus的设计优势及临床表现，该试验获得全球多中心积极参与，将持续加速推进试验进程。健世科技-B提醒投资者，根据香港联合交易所有限公司证券上市规则第18A.05条，概不保证LuX-Valve Plus最终能成功推向市场及/或商业化。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09877"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651413533","title":"健世科技-B(09877.HK)：经导管三尖瓣置换系统LuX-ValvePlus完成FDA批准的关键性注册临床试验(Pivotal Trial)的首批受试者植入","url":"https://stock-news.laohu8.com/highlight/detail?id=2651413533","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651413533?lang=zh_cn&edition=full","pubTime":"2026-07-16 12:23","pubTimestamp":1784175829,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["09877","BK1100"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649995181","title":"港股异动 | 健世科技-B(09877)涨超7% 经导管三尖瓣置换系统取得欧盟MDR CE认证","url":"https://stock-news.laohu8.com/highlight/detail?id=2649995181","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649995181?lang=zh_cn&edition=full","pubTime":"2026-07-08 09:54","pubTimestamp":1783475658,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，健世科技-B涨超7%，截至发稿，涨7.46%，报8.21港元，成交额125.77万港元。消息面上，健世科技今早公布，近日，集团自主研发的经导管三尖瓣置换系统 LuX-Valve Plus取得欧盟MDR CE认证，达成公司国际化战略的重要里程碑。公司表示正持续快速推进LuX-Valve Plus在欧洲以及全球的商业化进程，实现公司长期国际化战略目标。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1464508.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","CE","KCAI","VXUS","FESXmain","BK1100","FSXEmain","PSCM","09877","BK4585","BK4109"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649518139","title":"港股异动 | 健世科技-B(09877.HK)涨超7% 经导管三尖瓣置换系统取得欧盟MDR CE认证","url":"https://stock-news.laohu8.com/highlight/detail?id=2649518139","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649518139?lang=zh_cn&edition=full","pubTime":"2026-07-08 09:54","pubTimestamp":1783475658,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1100","09877"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649955634","title":"健世科技-B(09877)：经导管三尖瓣置换系统LuX-Valve Plus取得欧盟MDR CE认证","url":"https://stock-news.laohu8.com/highlight/detail?id=2649955634","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649955634?lang=zh_cn&edition=full","pubTime":"2026-07-08 08:02","pubTimestamp":1783468948,"startTime":"0","endTime":"0","summary":"智通财经APP讯，健世科技-B 发布公告，近日，集团自主研发的经导管三尖瓣置换系统 LuX-Valve Plus取得欧盟MDR CE认证，达成公司国际化战略的重要里程碑。LuX-Valve Plus是全球第二款获批的经导管塬位三尖瓣置换产品。公司正持续快速推进LuX-Valve Plus在欧洲以及全球的商业化进程，实现公司长期国际化战略目标。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1464458.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","09877","BK4109","PSCM","BK4585","FESXmain","FSXEmain","BK1100","CE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142319939","title":"健世科技-B（09877）自主研发LuX-Valve Plus获欧盟MDR CE认证","url":"https://stock-news.laohu8.com/highlight/detail?id=1142319939","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1142319939?lang=zh_cn&edition=full","pubTime":"2026-07-08 07:48","pubTimestamp":1783468083,"startTime":"0","endTime":"0","summary":"2026年7月8日，宁波健世科技股份有限公司发布自愿公告称，其自主研发的经导管三尖瓣置换系统LuX-Valve Plus已通过欧盟医疗器械法规CE认证，标志着公司国际化战略的重要里程碑。该产品成为全球第二款获批的经导管原位三尖瓣置换产品。LuX-Valve Plus采用经血管路径，配备室间隔锚定设计、自适应防漏裙边及多维可调弯输送系统，并提供40 mm至70 mm的七个规格型号，以覆盖广泛的三尖瓣反流临床需求。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09877"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125301447","title":"健世科技-B6月股份变动月报表，股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1125301447","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1125301447?lang=zh_cn&edition=full","pubTime":"2026-07-07 17:02","pubTimestamp":1783414921,"startTime":"0","endTime":"0","summary":"宁波健世科技股份有限公司于2026年7月7日发布2026年6月股份变动月报表，报告期截至2026年6月30日。报告显示，截至本月末，公司普通股下分为两类：在香港联交所上市的H股310,306,209股、非上市股106,861,081股，两者数量均与上月持平。根据月报，报告期内公司无新增发行、购回、注销或库存股变动，股本结构保持稳定。公司表示，已符合相关公共持股量要求，并确认遵守香港联交所《上市规则》及相关法律的规定。该报告由公司秘书李远源签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09877"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645490019","title":"健世科技-B(09877)：Ken-Valve获香港卫生署批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2645490019","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645490019?lang=zh_cn&edition=full","pubTime":"2026-06-22 06:29","pubTimestamp":1782080994,"startTime":"0","endTime":"0","summary":"智通财经APP讯，健世科技-B(09877)发布公告，公司的经导管人工主动脉瓣膜系统Ken-Valve已于近日取得中国香港特别行政区卫生署(香港卫生署)的批准，公司正积极推动该产品于中国香港地区的商业化。得益于产品的差异化优势、持续进行的疗法推广工作以及丰富的商业化应用经验，Ken-Valve已获得市场的广泛认可。本次Ken-Valve获香港卫生署批准，进一步验证了该产品在主动脉瓣反流(或合并狭窄)疗法的潜力。公司将继续全面加速Ken-Valve的全球商业化进程，以进一步实现公司长期战略目标。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1456642.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"健世科技-B(09877)：Ken-Valve获香港卫生署批准","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1100","09877"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111878878","title":"健世科技-B Ken-Valve经导管主动脉瓣置换系统获香港卫生署批准","url":"https://stock-news.laohu8.com/highlight/detail?id=1111878878","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1111878878?lang=zh_cn&edition=full","pubTime":"2026-06-22 06:07","pubTimestamp":1782079634,"startTime":"0","endTime":"0","summary":"健世科技-B宣布，其自主研发的Ken-Valve经导管主动脉瓣置换系统，已正式获得香港特别行政区卫生署的批准。这一关键性监管许可，标志着该创新医疗器械在拓展临床应用区域方面取得了重要进展，为其进入香港市场、服务更多患者铺平了道路。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09877","BK1100"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145245987","title":"健世科技-B更新2026年5月股份变动月报，股本保持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1145245987","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1145245987?lang=zh_cn&edition=full","pubTime":"2026-06-04 17:33","pubTimestamp":1780565583,"startTime":"0","endTime":"0","summary":"宁波健世科技股份有限公司（健世科技-B，股票代码：09877）于2026年6月4日披露截至2026年5月31日的股份变动月报。报告显示，H股已发行股份总数310,306,209股，非上市股份106,861,081股，注册股本合计417,167,290股，当月无新增发行、购回、注销或库藏股。\n根据月报，健世科技-B确认符合香港联交所最低17.32%的公众持股比例要求；同时，公司表示当月未发生任何股份期权、认股权证或可换股票据的发行或变动，股本结构总体保持稳定。\n该月报由公司秘书李远源签署，并确认公司持续遵守香港联交所《上市规则》及相关法律法规。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09877"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638365694","title":"新华健康 | 高瓴资本意欲何为？ 三度交易华医圣杰股权引追问","url":"https://stock-news.laohu8.com/highlight/detail?id=2638365694","media":"经济参考网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638365694?lang=zh_cn&edition=full","pubTime":"2026-05-28 22:30","pubTimestamp":1779978629,"startTime":"0","endTime":"0","summary":"同一公司，高瓴资本先将其卖给健世科技（09877.HK），两年后又从健世科技手中买回来。如今，高瓴资本又将其卖给先健科技（01302.HK）。这笔交易一经披露，随即引起业界关注：高瓴资本如此腾挪意欲何为？先健科技近日披露了最新的交易方案。按照协议，公司拟作价18.73亿元收购北京华医圣杰科技有限公司（简称“华医圣杰”）96.46%股权，交易对手穿透后由高瓴资本控制。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605283753111580.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1100","BK1600","BK1583","09877","01302"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637715878","title":"健世科技-B(09877)：LuX-Valve Plus EU TRINITY研究大瓣环患者12个月临床随访结果于EuroPCR 2026发布，展现产品大尺寸优势","url":"https://stock-news.laohu8.com/highlight/detail?id=2637715878","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637715878?lang=zh_cn&edition=full","pubTime":"2026-05-21 07:10","pubTimestamp":1779318617,"startTime":"0","endTime":"0","summary":"智通财经APP讯，健世科技-B 发布公告，近期，LuX-Valve Plus经血管三尖瓣介入置换系统的全球多中心临床试验研究中大瓣环患者12个月期临床随访结果于EuroPCR 2026发布，展现了其大尺寸优势，预期能够满足广泛的、未被满足的临床需求。LuX-Valve Plus EU TRINITY研究：大瓣环患者12个月期临床随访结果-由来自法国波尔多大学医院的Thomas Modine教授发布。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1444244.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"健世科技-B(09877)：LuX-Valve Plus EU TRINITY研究大瓣环患者12个月临床随访结果于EuroPCR 2026发布，展现产品大尺寸优势","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1100","09877","BK4156"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198973191","title":"健世科技-B发布2026年4月股份变动月报，股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1198973191","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1198973191?lang=zh_cn&edition=full","pubTime":"2026-05-07 17:00","pubTimestamp":1778144437,"startTime":"0","endTime":"0","summary":"宁波健世科技股份有限公司于2026年5月7日披露了截至2026年4月30日止的月度证券变动情况。公告显示，本月公司注册股本及已发行股份总数均未发生变动。根据报告，普通股H股于上月底及本月底的已发行股份数均为310,306,209股，库藏股份数保持为0股，已发行股份总数继续维持于310,306,209股。公司非上市股份亦保持在106,861,081股，均未出现变动。公司整体法定/注册股本总额与上月维持一致，为人民币417,167,290元。该公告由公司秘书李远源签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09877"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179044487","title":"健世科技-B（09877）2025年收入达9,058.70万元 加大心瓣膜介入研发致年内亏损扩大至2.73亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1179044487","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1179044487?lang=zh_cn&edition=full","pubTime":"2026-04-28 22:39","pubTimestamp":1777387184,"startTime":"0","endTime":"0","summary":"在经导管瓣膜领域深耕的健世科技-B于2025年实现突破性业务进展，全年收入录得人民币9,058.70万元；因研发与推广投入增长，年内亏损由上年度的人民币1.86亿元扩大至人民币2.73亿元。公司强调已进入商业化关键阶段，经导管三尖瓣、二尖瓣及主动脉瓣等多款自研器械产品在全球主要市场的注册审评取得积极进展，为后续市场开拓奠定基础。报告期内，公司心脏瓣膜介入治疗产品收入为人民币9,058.70万元，营业成本为人民币8.1百万元，毛利率约91.1%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"健世科技-B（09877）2025年收入达9,058.70万元 加大心瓣膜介入研发致年内亏损扩大至2.73亿元","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09877"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1151935263","title":"健世科技-B拟回购不超过10%已发行H股","url":"https://stock-news.laohu8.com/highlight/detail?id=1151935263","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1151935263?lang=zh_cn&edition=full","pubTime":"2026-04-28 22:35","pubTimestamp":1777386952,"startTime":"0","endTime":"0","summary":"宁波健世科技股份有限公司日前发布公告，称公司董事会已获股东大会特别决议案通过，拟于法定授权期间内回购不超过公司当日已发行H股总数10%的股份，并可自行决定将购回的股份作为库存股份持有或进行注销。该公司H股于香港联合交易所有限公司主板上市，截至最后可行日期，健世科技-B已发行H股约3.10亿股。其过去12个月期间，公司H股于二级市场的价格区间最高为11.98港元，最低为3.38港元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"健世科技-B拟回购不超过10%已发行H股","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09877"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178988863","title":"健世科技-B2026年3月股份变动月报：股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1178988863","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1178988863?lang=zh_cn&edition=full","pubTime":"2026-04-09 16:50","pubTimestamp":1775724658,"startTime":"0","endTime":"0","summary":"健世科技-B于2026年4月9日公布2026年3月股份变动月报。本次报告期为2026年3月1日至3月31日。公司披露，截至2026年3月31日，普通股总注册股本合计为人民币417,167,290元，其中在香港联合交易所上市的H股注册股本为人民币310,306,209元，非上市的内资股及非上市外资股注册股本为人民币106,861,081元。经公司确认，截至2026年3月31日，股本基本保持稳定，已满足香港联交所对最低公众持股量的要求。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09877"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623369471","title":"健世科技-B(09877)：iJensRobo机器人辅助TTVR系统完成首例人体临床研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2623369471","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623369471?lang=zh_cn&edition=full","pubTime":"2026-03-30 08:27","pubTimestamp":1774830421,"startTime":"0","endTime":"0","summary":"近期，本公司于香港完成iJensRobo机器人辅助TTVR系统首例患者临床研究。手术采用本公司iJensRobo机器人辅助TTVR系统，为一名重度三尖瓣反流患者成功植入LuX-Valve Plus瓣膜。iJensRobo机器人辅助TTVR系统结合高精度运动控制、主动安全约束机制及智能导航技术，可实现稳定且精细的器械操控，以支持关键操作步骤的安全性及可靠性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1421441.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1100","ROBO","09877"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1166924829","title":"异动解读 | 业绩利好提振信心，健世科技-B盘中大涨5.32%","url":"https://stock-news.laohu8.com/highlight/detail?id=1166924829","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1166924829?lang=zh_cn&edition=full","pubTime":"2026-03-27 15:18","pubTimestamp":1774595904,"startTime":"0","endTime":"0","summary":"健世科技-B今日盘中股价大幅上涨5.32%，表现强劲。消息面上，公司发布了截至2025年12月31日止年度的业绩报告。报告期内，集团取得收入人民币9060万元，其他收入及收益人民币1660万元，合计人民币1.07亿元。公司商业化首年即实现可观收入，展现了较强的商业化运作能力，市场对其未来收入稳定快速增长抱有积极预期，这显著增强了投资者信心，从而推动了股价的上涨。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["09877"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622862614","title":"健世科技-B(09877)：李远源将获委任为首席财务官","url":"https://stock-news.laohu8.com/highlight/detail?id=2622862614","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622862614?lang=zh_cn&edition=full","pubTime":"2026-03-27 00:03","pubTimestamp":1774541014,"startTime":"0","endTime":"0","summary":"智通财经APP讯，健世科技-B(09877)发布公告，潘斐先生将不再担任公司首席财务官，自2026年3月26日起生效。潘先生将继续担任公司执行董事、首席执行官、就香港联交所证券上市规则第3.05条而言的授权代表及公司战略委员会成员。李远源先生将获委任为公司首席财务官，负责公司及其附属公司的整体财务管理、投资融资管理、投资者关系、商业运营及公共事务，自2026年3月26日起生效。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1420077.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"健世科技-B(09877)：李远源将获委任为首席财务官","news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09877","BK1100"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622862577","title":"健世科技-B(09877)发布年度业绩，商业化首年实现收入9060万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2622862577","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622862577?lang=zh_cn&edition=full","pubTime":"2026-03-27 00:01","pubTimestamp":1774540902,"startTime":"0","endTime":"0","summary":"智通财经APP讯，健世科技-B 发布截至2025年12月31日止年度业绩，本集团持续推进其结构性心脏病介入产品全球商业化发展战略。于报告期内，本集团取得收入人民币9060万元，其他收入及收益人民币1660万元，合计人民币1.07亿元。公司商业化首年即实现可观收入，展现了公司团队较高的商业化运作能力。通过覆盖三尖瓣、主动脉瓣、二尖瓣等疾病的产品布局，公司已形成高增长、全面化、具备全球竞争力的核心产品矩阵。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1420073.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1100","09877"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.jenscare.com","stockEarnings":[{"period":"1week","weight":0.0053},{"period":"1month","weight":0.1},{"period":"3month","weight":-0.2302},{"period":"6month","weight":-0.056},{"period":"1year","weight":-0.105},{"period":"ytd","weight":-0.1472}],"compareEarnings":[{"period":"1week","weight":0.0163},{"period":"1month","weight":0.0662},{"period":"3month","weight":-0.0391},{"period":"6month","weight":-0.0668},{"period":"1year","weight":-0.0274},{"period":"ytd","weight":-0.026}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"宁波健世科技股份有限公司是一家主要从事治疗结构性心脏病的介入产品及其他相关医疗产品研发的中国公司。该公司针对不同类型结构性心脏病，包括三尖瓣疾病、主动脉瓣疾病、二尖瓣疾病、心力衰竭及心源性卒中，开发一系列治疗解决方案。该公司的产品及管线主要包括LuX-Valve、LuX-Valve Plus、Ken-Valve、JensClip、JensRelive、MicroFlux和SimuLock。LuX-Valve是第一代经导管三尖瓣置换系统，为治疗有重度三尖瓣返流及高手术风险的患者而设计。Ken-Valve是第一代经导管主动脉瓣置换系统，为治疗重度主动脉瓣返流或合并主动脉瓣狭窄的患者而设计。","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":-0.136162},{"month":2,"riseRate":0.5,"avgChangeRate":0.00774},{"month":3,"riseRate":0.25,"avgChangeRate":-0.133402},{"month":4,"riseRate":0.5,"avgChangeRate":0.073914},{"month":5,"riseRate":0.25,"avgChangeRate":-0.008582},{"month":6,"riseRate":0.25,"avgChangeRate":-0.031042},{"month":7,"riseRate":0.75,"avgChangeRate":0.053194},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.125483},{"month":9,"riseRate":0.666667,"avgChangeRate":0.130455},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.099341},{"month":11,"riseRate":0.5,"avgChangeRate":0.085892},{"month":12,"riseRate":0.75,"avgChangeRate":0.091534}],"exchange":"SEHK","name":"健世科技-B","nameEN":"JENSCARE-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"健世科技-B(09877)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供健世科技-B(09877)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"健世科技-B,09877,健世科技-B股票,健世科技-B股票老虎,健世科技-B股票老虎国际,健世科技-B行情,健世科技-B股票行情,健世科技-B股价,健世科技-B股市,健世科技-B股票价格,健世科技-B股票交易,健世科技-B股票购买,健世科技-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"健世科技-B(09877)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供健世科技-B(09877)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}